Nonetheless, we observed significant protection of pancreatic cancer cells from gemcitabine toxicity on co-treatment with exogenous CXCL12, indicating a role for CXCL12–CXCR4 signalling axis in pancreatic cancer chemoresistance. The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.